The expression and prognosis of Emi1 and Skp2 in breast carcinoma: Associated with PI3K/Akt pathway and cell proliferation

Medical Oncology

Volumn 30, Issue 4, 2013, Pages

  Liu, Xiaobing ^a   Wang, Hua ^a   Ma, Jing ^a   Xu, Junfei ^a   Sheng, Chenyi ^a   Yang, Shuyun ^a   Sun, Lingling ^a   Ni, Qichao ^a  

^a NANTONG UNIVERSITY   (China)

Author keywords

Breast cancer; Emi1; PI3K Akt; Prognosis; Skp2

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; CYCLIN DEPENDENT KINASE INHIBITOR 1B; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; S PHASE KINASE ASSOCIATED PROTEIN 2; CELL CYCLE PROTEIN; F BOX PROTEIN; FBXO5 PROTEIN, HUMAN; S PHASE KINASE ASSOCIATED PROTEIN;

ADULT; AGED; APOPTOSIS; ARTICLE; BREAST CARCINOMA; CANCER PROGNOSIS; CARCINOMA CELL; CELL CYCLE ARREST; CELL GROWTH; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; DRUG TARGETING; EMI1 GENE; FEMALE; GENE; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MIDDLE AGED; MOLECULAR INTERACTION; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SURVIVAL RATE; UPREGULATION; WESTERN BLOTTING; YOUNG ADULT; BIOSYNTHESIS; BREAST TUMOR; CHEMISTRY; GENETICS; KAPLAN MEIER METHOD; METABOLISM; PROGNOSIS; SIGNAL TRANSDUCTION; STATISTICAL MODEL; TUMOR CELL LINE; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CELL CYCLE PROTEINS; CELL LINE, TUMOR; F-BOX PROTEINS; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LINEAR MODELS; MIDDLE AGED; PHOSPHATIDYLINOSITOL 3-KINASES; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-AKT; S-PHASE KINASE-ASSOCIATED PROTEINS; SIGNAL TRANSDUCTION; YOUNG ADULT;

MLCS; MLOWN;

EID: 84886039601     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-013-0735-0     Document Type: Article

References (38)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55:74-108. (Pubitemid 40372904)
2. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69-90.
3. Johnson DG, Walker CL. Cyclins and cell cycle checkpoints. Annu Rev Pharmacol Toxicol. 1999;39:295-312. (Pubitemid 29222561)
4. Guardavaccaro D, Kudo Y, Boulaire J, et al. Control of meiotic and mitotic progression by the F box protein beta-Trcp1 in vivo. Dev Cell. 2003;4:799-812. (Pubitemid 36676033)
5. (Cdh1). Nat Cell Biol. 2002;4:358-66. (Pubitemid 34521031)
6. Margottin-Goguet F, Hsu JY, Loktev A, et al. Prophase destruction of Emi1 by the SCF(betaTrCP/Slimb) ubiquitin ligase activates the anaphase promoting complex to allow progression beyond prometaphase. Dev Cell. 2003;4:813-26. (Pubitemid 36676034)
7. Reimann JD, Gardner BE, Margottin-Goguet F, Jackson PK. Emi1 regulates the anaphase-promoting complex by a different mechanism than Mad2 proteins. Genes Dev. 2001;15:3278-85. (Pubitemid 34013499)
8. Miller JJ, Summers MK, Hansen DV, et al. Emi1 stably binds and inhibits the anaphase-promoting complex/cyclosome as a pseudosubstrate inhibitor. Genes Dev. 2006;20:2410-20. (Pubitemid 44320389)
9. Gutgemann I, Lehman NL, Jackson PK, Longacre TA. Emi1 protein accumulation implicates misregulation of the anaphase promoting complex/cyclosome pathway in ovarian clear cell carcinoma. Mod Pathol. 2008;21:445-54. (Pubitemid 351441034)
10. Lehman NL, Tibshirani R, Hsu JY, et al. Oncogenic regulators and substrates of the anaphase promoting complex/cyclosome are frequently overexpressed in malignant tumors. Am J Pathol. 2007;170:1793-805. (Pubitemid 47339321)
11. Schaner ME, Ross DT, Ciaravino G, et al. Gene expression patterns in ovarian carcinomas. Mol Biol Cell. 2003;14:4376-86. (Pubitemid 37444641)
12. Wang Q, Moyret-Lalle C, Couzon F, et al. Alterations of anaphase-promoting complex genes in human colon cancer cells. Oncogene. 2003;22:1486-90. (Pubitemid 36390597)
13. Shapira M, Kakiashvili E, Rosenberg T, Hershko DD. The mTOR inhibitor rapamycin down-regulates the expression of the ubiquitin ligase subunit Skp2 in breast cancer cells. Breast Cancer Res. 2006;8:R46. (Pubitemid 44263034)
14. Liu W, Asa SL, Fantus IG, et al. Vitamin D arrests thyroid carcinoma cell growth and induces p27 dephosphorylation and accumulation through PTEN/akt-dependent and -independent pathways. Am J Pathol. 2002;160:511-9. (Pubitemid 34160328)
15. Gstaiger M, Jordan R, Lim M, et al. Skp2 is oncogenic and overexpressed in human cancers. Proc Natl Acad Sci USA. 2001;98:5043-8. (Pubitemid 32397079)
16. Masuda TA, Inoue H, Sonoda H, et al. Clinical and biological significance of S-phase kinase-associated protein 2 (Skp2) gene expression in gastric carcinoma: modulation of malignant phenotype by Skp2 overexpression, possibly via p27 proteolysis. Cancer Res. 2002;62:3819-25. (Pubitemid 34728867)
17. Signoretti S, Di Marcotullio L, Richardson A, Ramaswamy S, Isaac B, Rue M, Monti F, Loda M, Pagano M. Oncogenic role of the ubiquitin ligase subunit Skp2 in human breast cancer. J Clin Invest. 2002;110:633-41. (Pubitemid 34988787)
18. Yang G, Ayala G, De Marzo A, et al. Elevated Skp2 protein expression in human prostate cancer: association with loss of the cyclin-dependent kinase inhibitor p27 and PTEN and with reduced recurrence-free survival. Clin Cancer Res. 2002;8:3419-26. (Pubitemid 35340716)
19. Traub F, Mengel M, Luck HJ, et al. Prognostic impact of Skp2 and p27 in human breast cancer. Breast Cancer Res Treat. 2006;99:185-91. (Pubitemid 44268266)
20. Zheng WQ, Zheng JM, Ma R, Meng FF, Ni CR. Relationship between levels of Skp2 and P27 in breast carcinomas and possible role of Skp2 as targeted therapy. Steroids. 2005;70:770-4. (Pubitemid 41169911)
21. Gao D, Inuzuka H, Tseng A, et al. Phosphorylation by Akt1 promotes cytoplasmic localization of Skp2 and impairs APCCdh1-mediated Skp2 destruction. Nat Cell Biol. 2009;11:397-408.
22. Lin HK, Wang G, Chen Z, et al. Phosphorylation-dependent regulation of cytosolic localization and oncogenic function of Skp2 by Akt/PKB. Nat Cell Biol. 2009;11:420-32.
23. Gesbert F, Sellers WR, Signoretti S, et al. BCR/ABL regulates expression of the cyclin-dependent kinase inhibitor p27Kip1 through the phosphatidylinositol 3-Kinase/AKT pathway. J Biol Chem. 2000;275:39223-30. (Pubitemid 32058940)
24. Murillo H, Huang H, Schmidt LJ, et al. Role of PI3K signaling in survival and progression of LNCaP prostate cancer cells to the androgen refractory state. Endocrinology. 2001;142:4795-805. (Pubitemid 33022355)
25. Pene F, Claessens YE, Muller O, et al. Role of the phosphatidylinositol 3-kinase/Akt and mTOR/P70S6-kinase pathways in the proliferation and apoptosis in multiple myeloma. Oncogene. 2002;21:6587-97. (Pubitemid 35177037)
26. Liu J, Wei XL, Huang WH, Chen CF, Bai JW, Zhang GJ. Cytoplasmic Skp2 expression is associated with p-Akt1 and predicts poor prognosis in human breast carcinomas. PLoS ONE. 2012;7:e52675.
27. Remmele W, Muhlfait V, Keul HG. Estimation of the proliferative activity of human breast cancer tissue by means of the Ki-67 and MIB-1 antibodies-comparative studies on frozen and paraffin sections. Virchows Arch. 1995;426:435-9.
28. Hansen DV, Loktev AV, Ban KH, Jackson PK. Plk1 regulates activation of the anaphase promoting complex by phosphorylating and triggering SCFbetaTrCP-dependent destruction of the APC Inhibitor Emi1. Mol Biol Cell. 2004;15:5623-34. (Pubitemid 39564753)
29. Machida YJ, Dutta A. The APC/C inhibitor, Emi1, is essential for prevention of rereplication. Genes Dev. 2007;21:184-94. (Pubitemid 46155812)
30. Ewerth D, Schmidts A, Kuegelgen B, Wider D, Schuler J, Engelhardt M, Wasch R. Dissecting stem cell proliferation and differentiation in association with the central cell cycle regulator APC/CCdh1. Blood (ASH Annual Meeting Abstracts). 2012;120:Abstract 1236.
31. Catzavelos C, Bhattacharya N, Ung YC, et al. Decreased levels of the cell-cycle inhibitor p27Kip1 protein: prognostic implications in primary breast cancer. Nat Med. 1997;3:227-30. (Pubitemid 27064710)
32. Mori M, Mimori K, Shiraishi T, et al. p27 expression and gastric carcinoma. Nat Med. 1997;3:593. (Pubitemid 27264950)
33. Chiarle R, Pagano M, Inghirami G. The cyclin dependent kinase inhibitor p27 and its prognostic role in breast cancer. Breast Cancer Res. 2001;3:91-4. (Pubitemid 32266276)
34. Vazquez F, Sellers WR. The PTEN tumor suppressor protein: an antagonist of phosphoinositide 3-kinase signaling. Biochim Biophys Acta. 2000;1470:M21-35.
35. Burgering BM, Medema RH. Decisions on life and death: FOXO Forkhead transcription factors are in command when PKB/Akt is off duty. J Leukoc Biol. 2003;73:689-701. (Pubitemid 38040447)
36. Plas DR, Thompson CB. Akt activation promotes degradation of tuberin and FOXO3a via the proteasome. J Biol Chem. 2003;278:12361-6. (Pubitemid 36800220)
37. Kulik G, Carson JP, Vomastek T, et al. Tumor necrosis factor alpha induces BID cleavage and bypasses antiapoptotic signals in prostate cancer LNCaP cells. Cancer Res. 2001;61:2713-9. (Pubitemid 32685859)
38. Izuishi K, Kato K, Ogura T, et al. Remarkable tolerance of tumor cells to nutrient deprivation: possible new biochemical target for cancer therapy. Cancer Res. 2000;60:6201-7.